Secondary Logo

Institutional members access full text with Ovid®

Liver disease in patients with cystic fibrosis

Kamal, Natashaa; Surana, Pallavib; Koh, Christopherb

Current Opinion in Gastroenterology: May 2018 - Volume 34 - Issue 3 - p 146–151
doi: 10.1097/MOG.0000000000000432
LIVER: Edited by Don C. Rockey
Buy

Purpose of review The aim of this study was to provide an overview of the current understanding of the pathophysiology, diagnosis and management of cystic fibrosis-liver disease (CFLD).

Recent findings CFLD has a variety of manifestations. Previously, it was thought that patients progressed from mild cholestatic disease to cirrhosis to decompensated cirrhosis with portal hypertension. Newer evidence suggests that some patients may develop cirrhosis while others develop noncirrhotic portal hypertension. Advances in our understanding of the pathophysiology of disease necessitate modifications to the current diagnostic criteria. Both fibroscan and noninvasive biomarkers can be used to identify patients with cirrhosis and portal hypertension. Ursodeoxycholic acid remains the mainstay of therapy despite a paucity of rigorous studies supporting its use. Novel therapeutic agents such as CF transmembrane conductance regulator (CFTR) modulators and potentiators are encouraging but need to be evaluated specifically in CFLD.

Summary A better understanding of the pathophysiology of disease is critical to developing more disease-specific diagnostics and therapeutics.

aDigestive Diseases Branch

bLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

Correspondence to Christopher Koh, Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Building 10-CRC, Room 5-2740, 10 Center Drive, Bethesda, MD 20892, USA. Tel: +1 301 451 0659; e-mail: christopher.koh@nih.gov

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.